According to the website of the National Medical Products Administration, on December 9th, Li Li, Secretary and Director of the Party Group of the National Medical Products Administration, presided over a Party group meeting to study and deploy drug regulatory talent work, and reviewed the "Implementation Opinions on Strengthening Drug Regulatory Talent Work in the New Era". The meeting pointed out that talent is the fundamental and strategic support for comprehensively strengthening drug regulatory capacity building and achieving modernization of drug regulation. Strengthening the work of drug regulatory talents is an important measure to implement the spirit of the 20th National Congress of the Communist Party of China and its plenary sessions, as well as the spirit of the Central Conference on Talent Work. It is an inevitable requirement to promote the high-quality development of talent work throughout the system, and is of great significance for ensuring drug safety and promoting the development of the pharmaceutical industry. The meeting emphasized the need to deepen the reform of the talent development system and mechanism, focus on the construction of core professional teams such as drug review and approval, inspection and testing, standard development, monitoring and evaluation, continuously improve the talent training mechanism, reform the talent evaluation mechanism, improve the talent incentive mechanism, innovate the talent flow mechanism, and strive to build a high-quality drug regulatory talent team with strong political integrity, excellent business skills, appropriate scale, and reasonable structure, providing strong support for promoting the modernization of drug regulation. The meeting called for strengthening the overall coordination and guidance of talent work across the system, implementing the political responsibility of drug regulatory departments at all levels to manage talent, timely resolving bottlenecks and difficulties in talent work, ensuring the implementation of various tasks in talent work, and striving to promote drug regulatory talent work to a new level. (New Society)